ORGANOVO Forum: Community User: Trader_100

Keine konkreten. Die 3D Branche wurde bei schwachem Gesamtmarkt wieder stark verkauft. Habe keine spezifischen News zu Onovo gefunden. Bald kommen aber Zahlen.

Was zum teufel passiert gerade? Rising star hast du infos, warums so steil bergab geht?

Hier trägt natürlich die Stinmung des Gesamtmarktes und die der 3D Branche zu bei. Ich hoffe auf eine Überraschung am 8.2.

Hmm bald Pennystock

Organovo Announces Release Date for Fiscal Third-Quarter 2016 Financial Results 01/19/2016 SAN DIEGO, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, will host a conference call on Monday, February 8, 2016 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal third-quarter 2016 financial results. In advance of the call on February 8, 2016, Organovo will issue its fiscal third-quarter 2016 earnings press release, which will be available at http://www.organovo.com. To participate in the teleconference, callers can dial the following numbers: 1-888-317-6003 (toll-free, U.S. callers only) 1-412-317-6061 (from outside the U.S.) Conference Call ID: 5006379

Organovo Subsidiary Samsara Sciences Launches Commercial Operations 01/13/2016 SAN DIEGO, Jan. 13, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) (“Organovo” or the “Company”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that its wholly-owned subsidiary, Samsara Sciences, Inc. (“Samsara”), has launched commercial operations. Samsara’s core mission is the provision of high-quality primary human liver cells for a wide variety of in vivo and in vitro research applications. Samsara is expected to serve as a key source of primary human liver cells for Organovo’s needs in the preclinical safety and therapeutic tissues markets, allowing the Company to optimize its supply chain and operating expenses related to cell sourcing and procurement. Organovo sought to establish Samsara as a cell provider in part to support the needs of high-quality cell supply for use in the research and development of bioprinted liver tissue as a potential therapeutic product. Samsara will also provide such cells to life science customers through typical commercial channels. Samsara will offer a comprehensive selection of human hepatic stellate cells – a key cell type in the liver that plays a major role in the development of prevalent diseases such as fatty liver disease and fibrosis. In addition to receiving detailed culture and cryopreservation protocols with each lot of cells, Samsara’s customers will have access to a full portfolio of companion services including the provision of tissue sections, nucleic acids and gene expression data. Human hepatocytes will also be made available through established distribution channels. To achieve its goals, Samsara works closely with key collaborator and liver cell biology expert, Dr. Tatiana Kisseleva and her laboratory at the University of California, San Diego School of Medicine. “The Samsara team shares a passion for cells and is dedicated to providing the high-quality, well-characterized cellular reagents that are required to support the future of biological research and tissue products," said Dr. Sharon Presnell, President, Samsara Sciences and Chief Technology Officer and Executive Vice President of Research & Development, Organovo. “Our ultimate vision is to supply a comprehensive portfolio of tissue-specific cells that are tailored for use in the production of the multi-cellular 3D tissues that are poised to change the landscape of drug discovery and regenerative medicine.” “Cell supply and quality are critical to meeting Organovo’s goal to change the shape of medical research and practice, including our desire to create a bioprinted liver patch for transplant,” said Keith Murphy, CEO, Organovo. “I’m grateful to the team at Samsara and its key collaborators and scientific advisors for enabling us to develop this high-quality cell source, and to offer it to other researchers through Samsara’s commercial efforts.”

Geht noch weiter runter.

2 USD ...Zeit zum Einstieg ?

Wohl doch bis zum 52-Wochen-Tief.. bin trotzdem entspannt.

Was ist da jetzt los, minus 6 prozent in einer std?

Nachlegen

Oder es geht bis übers allzeit Tief abwärts

Zuletzt ging es von hier (2,1 €) zugig bis zur 3,-

Gut, dass ich nochmal den Kurs gedrückt hatte

Geht immer weiter bergab :(

Ich rechne mit weiteren Fortschritten und dementsprechend guten News 2016.